Immatics N.V.

IPO

Immatics

Public · Tuebingen, Germany · Founded 2000 · $346.7M raised

Headquarters
Tuebingen
Employees
201–500
Founded
2000
Business Model
B2B
Total Funding
$346.7M
Last Round
$125.0M Corporate RoundDec 2025
Rounds
8
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Immatics N.V. is a clinical-stage biopharmaceutical company founded in 2000 as a spin-out from the University of Tübingen, Germany. The company is the global leader in PRAME-targeted cancer immunotherapy, developing both T cell receptor-based adoptive cell therapies (ACTengine®) and TCR bispecifics across more than 50 cancer indications.

Summary

Immatics N.V. is a Biotech company based in Tuebingen, Germany, founded in 2000. It has raised $346.7M in total across 8 rounds, most recently a $125.0M Corporate Round in Dec 2025. Investors include Wellington Management, Wellington Partners Venture Capital and Jefferies.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Corporate RoundCorporate RoundDec 2025
$125.0M

Sign up to see all 9 events

Funding: Series A through Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Immatics N.V. on Indexed.vc
<a href="https://indexed.vc/companies/immatics-n-v"><img src="https://indexed.vc/api/badge/company/immatics-n-v" alt="Immatics N.V. on Indexed.vc" width="260" height="76" /></a>